Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):7-24. doi: 10.1038/s41575-023-00840-w. Epub 2023 Oct 5.
Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most lethal human malignancies. Much is known regarding the biology and pathophysiology of PDAC, but translating this knowledge to the clinic to improve patient outcomes has been challenging. In this Review, we discuss advances and practice-changing trials for PDAC. We briefly review therapeutic failures as well as ongoing research to refine the standard of care, including novel biomarkers and clinical trial designs. In addition, we highlight contemporary areas of research, including poly(ADP-ribose) polymerase inhibitors, KRAS-targeted therapies and immunotherapies. Finally, we discuss the future of pancreatic cancer research and areas for improvement in the next decade.
胰腺导管腺癌（PDAC）的发病率不断上升，是最致命的人类恶性肿瘤之一。人们对 PDAC 的生物学和病理生理学有了很多了解，但将这些知识转化到临床实践中以改善患者预后一直具有挑战性。在这篇综述中，我们讨论了 PDAC 的进展和改变实践的试验。我们简要回顾了治疗失败以及正在进行的研究，以完善标准治疗，包括新的生物标志物和临床试验设计。此外，我们还强调了当代研究领域，包括聚（ADP-核糖）聚合酶抑制剂、KRAS 靶向治疗和免疫疗法。最后，我们讨论了未来十年胰腺癌症研究和改进领域。
